Pancragen trail: terminally amidated KEDW — RU2242241C1
В.Х. Хавинсон (RU), В.Х. Хавинсон, В.В. Малинин (RU), В.В. Малинин, Е.И. Григорьев (RU), Е.И. Григорьев, Г.А. Рыжак (RU), Г.А. Рыжак · 2004 · RU2242241C1 · patent family 34388701
Published 2004-12-20.
Reported patent results
Reported findings
Selected cases report lower glucose and reduced background medication requirements; no independent peptide effect is established.
Pancragen-related KEDW-NH2 patent diabetes case examples during ongoing insulin or oral antidiabetic care.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Insulin-treated case | Fasting glucose 17.8 → 3.4 mmol/L; insulin 40 → 32 units/day | One individual; concurrent care continued · Discharge on day 15 |
| Oral-treatment case | Fasting glucose 11 → 6 mmol/L by day 2; background oral drug subsequently reduced | One selected patient, not a randomized comparison · Day 2 and subsequent course |
| Another insulin-treated case | Discharge glucose 5.9 mmol/L; insulin 56 units/day, reported 26 units below baseline | Individual observation · Day 18 |
Insulin adjustment, diet, inpatient care and selection prevent attribution. No long-term HbA1c, controlled remission or diabetes-cure estimate is established; the patent specifies an amidated peptide.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. The patent describes Lys-Glu-Asp-Trp with a terminal amide, alongside pancreatic-function applications.
Terminal chemistry matters: the claimed KEDW-NH2 must not be assumed identical to every KEDW product with a free acid terminus.
- Publication
- RU2242241C1 ↗ · 2004-12-20
- Earliest priority / filing
- 2003-12-10 / 2003-12-10
- Original applicant / assignee
- Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 34388701 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapeptide regulating glucose level in diabetes mellitus, pharmacological agent based on thereof and method for its applying
Inventors: В.Х. Хавинсон (RU); В.Х. Хавинсон; В.В. Малинин (RU); В.В. Малинин; Е.И. Григорьев (RU); Е.И. Григорьев; Г.А. Рыжак (RU); Г.А. Рыжак.
RU2242241C1 · US7491703B2 · EP1697401B1 · JP2007537140A · KR101106609B1 · ATE454397T1 · AU2004296269B2 · CA2547873C · DE602004025040D1 · DK1697401T3 · EA008541B1 · LT5421B · LV13462B · UA85204C2 · WO2005056580A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Terminal chemistry matters: the claimed KEDW-NH2 must not be assumed identical to every KEDW product with a free acid terminus.
- Insulin adjustment, diet, inpatient care and selection prevent attribution. No long-term HbA1c, controlled remission or diabetes-cure estimate is established; the patent specifies an amidated peptide.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-34388701. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: В.Х. Хавинсон (RU), В.Х. Хавинсон, В.В. Малинин (RU), В.В. Малинин, Е.И. Григорьев (RU), Е.И. Григорьев, Г.А. Рыжак (RU), Г.А. Рыжак. Pancragen trail: terminally amidated KEDW — RU2242241C1 RU2242241C1 · patent family 34388701 2004.
Molekul research summary: https://molekul.io/research/patent-ru2242241c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry